MedTrace Logo

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

NCT04216121 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2024-07-01

No results posted yet for this study

Summary

To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = \>3 months).

Conditions

  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Interventions

RADIATION

Local ablative therapy

Stereotactic body radiotherapy

PROCEDURE

Local ablative therapy

Surgery

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04216121 on ClinicalTrials.gov